BHVN-OLD
BIOHAVEN PHARMACEUTICAL HOLD
BIOHAVEN PHARMACEUTICAL HOLD historical holders
total: 1
Viking Global Investors BIOHAVEN PHARMACEUTICAL HOLD transactions over time
- Total transactions:
- 3
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Held since:
- 2021 Q4
- Held for:
- 2 quarters
- Latest activity:
- 2022 Q2
Ole Andreas Halvorsen has been an institutional investor in BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) since 2021 Q4. According to 2026 Q2 report, Ole Andreas Halvorsen doesn't hold any shares. The fund/company first acquired BHVN-OLD in 2021 Q4, initially purchasing 348,783 shares. Since the initial investment, Viking Global Investors has made 2 more transactions in this position.
When did Ole Andreas Halvorsen exit their BHVN-OLD position?
Ole Andreas Halvorsen no longer holds BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD). They sold off their entire position in 2022 Q2, closing out an investment that began in 2021 Q4.
When did Ole Andreas Halvorsen first invest in BHVN-OLD?
Ole Andreas Halvorsen first invested in BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) in 2021 Q4 at the reported quarter-end price of $137.81 per share, acquiring 348,783 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for BHVN-OLD?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for BIOHAVEN PHARMACEUTICAL HOLD (BHVN-OLD) is approximately $125.52 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $125.52
- Weighted AVG sell price:
- $118.57
BHVN-OLD transactions history by Viking Global Investors
3 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2022 Q2
|
0.00%
|
0
|
$118.57
|
|
-100% (-966,139)
|
-0.46%
|
|
2022 Q1
|
0.46%
|
966,139
|
$118.57
|
$114,555,000
|
+177.00% (+617,356)
|
+0.3%
|
|
2021 Q4
|
0.14%
|
348,783
|
$137.81
|
$48,066,000
|
new
|
+0.14%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.